secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0001664710-25-000057
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics concludes strategic review, plans $375M capital return
-------------------------------------------------------------------------

- Board unanimously approved $375M excess capital return to stockholders; structure and terms to be announced.
- Strategic review included evaluation of sale, business combination, and continued investment; outreach to third parties and stockholders.
- Company to continue development of lead candidate KER-065 for Duchenne muscular dystrophy.
- 2025 annual meeting results: all three director nominees elected, Deloitte & Touche ratified, executive compensation approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000057/0001664710-25-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000057/kros-20250604.htm
  HTML page:      https://secwatch.observer/filing/0001664710-25-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer